

# AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**Drug Requested:** Xifaxan<sup>®</sup> (rifaximin)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member AvMed #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight: \_\_\_\_\_ Date: \_\_\_\_\_

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Provider Please Note:** Xifaxan is NOT approved by the United States Food and Drug Administration (FDA) for the treatment of Small Intestinal Bacterial Overgrowth (SIBO)

(Continued on next page)

<b>Diagnosis:</b>	<input type="checkbox"/> <b>Hepatic Encephalopathy</b>	<input type="checkbox"/> <b>Irritable bowel syndrome with Diarrhea</b>	<input type="checkbox"/> <b>Traveler's Diarrhea</b>
<b>Trial and Failure:</b>	<input type="checkbox"/> Lactulose - 20 to 30 g (30 to 45 mL) 3 to 4 times daily	<input type="checkbox"/> History of failure, contraindication or intolerance to <b>THREE (3)</b> of the following <b>(verified by pharmacy paid claims; please submit chart notes to confirm treatment failure or intolerance):</b> <ul style="list-style-type: none"> <li><input type="checkbox"/> Antispasmodic agent (e.g., dicyclomine)</li> <li><input type="checkbox"/> Antidiarrheal agent (e.g., diphenoxylate/atropine)</li> <li><input type="checkbox"/> Tricyclic antidepressant (e.g., amitriptyline)</li> <li><input type="checkbox"/> Dietary Changes (e.g., low FODMAP diet, fiber supplementation, gluten-free diet)</li> </ul>	
<b>Dose:</b>	<input type="checkbox"/> 550 mg BID daily <input type="checkbox"/> 400 mg TID	<input type="checkbox"/> 550 mg TID for 14 days only	<input type="checkbox"/> 200 mg TID for 3 days only
<b>Re-Auth:</b>		<input type="checkbox"/> Another 14 days only. Has 4 months elapsed since last Xifaxan <sup>®</sup> dose?	<input type="checkbox"/> Last dose: _____ Approval will be for 3 days only

*Not all drugs may be covered under every Plan.*

*If a drug is non-formulary on a Plan, documentation of medical necessity will be required*

*\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria.\*\**

*\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\**